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Abstract We report the isolation and characterization of a novel 
peptide with significant sequence homology to 0-defensins from 
human blood filtrate. The human 0-defensin-I (hBD-I) is a short 
basic peptide of 36 amino acid residues. It contains six cysteines 
forming three intramolecular disulfide bonds. The molecular mass 
of hBD-1 is 3928.6 Da. Cloning of the specific cDNA confirmed 
the amino acid sequence of the native peptide, hBD-1 shares the 
nine conserved amino acids characteristic for ~B-defensins from 
respiratory epithelial cells and neutrophils of cattle and chicken 
leukocytes, hBD-1 is present in nanomolar concentration in 
human plasma. 
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I. Introduction 
Small basic antibiotic peptides are part of the unspecific host 
defense system existing in all animals [1,2]. In vertebrates they 
are abundant  in granules of phagocytic leukocytes as has been 
shown for protegrins [3], bactenecins [4], indolicidin [5], defen- 
sins [6], and fl-defensins [7] of mammals  and gallinacins from 
chicken [8]. In addit ion antimicrobial  peptides are present in 
different epithelial cells establishing an antimicrobial barrier, 
For  example, magainines have been identified in frog skin [9] 
and stomach [10], cecropin P1 in porcine small intestine [11], 
cryptdins in mouse small intestine [12], defensins in human 
small intestine [13], and tracheal antimicrobial peptide (TAP) 
in bovine trachea [14]. 
Recently we have improved the large-scale xtraction of  pep- 
tides from human hemofiltrate (HF) earlier described [15]. HF  
is obtained from patients with end stage renal disease (ESRD) 
undergoing hemofi l trat ion for the el imination of uremic toxins 
[16]. HF  quantitatively contains all small peptides present in 
plasma and can be considered to be a prepurified source of 
peptides from blood plasma [17]. We started a systematic inves- 
t igation of peptides from HF  [18]. In the course of this program 
a novel peptide hBD- 1 homologous to fl-defensins was isolated. 
2. Experimental 
2.1. Peptide extraction 
HF from approximately 25 individuals was collected, cooled to 4 ° C, 
acidified to pH 3.0 with HCI, and diluted with deionized water to a final 
conductivity of 5.5 mS/cm. 800 litre equivalents of HF were applied to 
a cation-exchange column (25 x 7 cm, Fraktogel SP-650 (M), Merck, 
Darmstadt, Germany). Bound proteins and peptides were eluted in 
5 litres with 1 M NaC1 and precipitated with ammonium sulfate (680 
g/l). Six precipitates representing 4800 litres of HF were dissolved in 
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2 litres of deionized water. Proteins were removed by ultrafiltration 
through a cellulose triacetate membrane with a cut-off of 20 kDa 
(Sartorius, G6ttingen, Germany). The ultrafiltrate containing the pep- 
tides was further used in the isolation procedure. 
2.2. Purification of hBD-1 
Step 1. The ultrafiltrate was diluted with deionized water to a final 
conductivity of 5.5 mS/cm, pH 3.0. In two runs the ultrafiltrate was 
chromatographed on a cation-exchange column (6 × 20 cm; Fraktogel 
SP-650 (M)) equilibrated with buffer A (0.1 M acetic acid, 20% metha- 
nol, pH 3.0). After a 30 min wash the peptides were eluted in a linear 
gradient from 100% buffer A to 40% buffer B (0.5 M acetic acid, 20% 
methanol, I M ammoniumacetate, pH 5.5) in 60 min and 40% to 100% 
buffer B in 10 min. Absorbance at 280 nm and conductivity were 
monitored. The flow rate was 50 ml/min and starting at min 10, 2 min 
fractions were collected. Corresponding fractions of both runs were 
pooled and lyophilized. 
Step 2. 100 mg from a total of 2.4 g of fraction 40 from step 1 were 
dissolved in 0.1% TFA and applied to a Parcosil C4 RP-HPLC column 
(10 × 125 mm, 5 pm, 300/k; Biotek, Ostringen, Germany). The mobile 
phases used for RP-HPLC were solvent A (0.1% TFA) and solvent B 
(0.1% TFA, 80% acetonitrile). Peptides were eluted with a linear gradi- 
ent from 5% to 50% solvent B in 45 rain. Absorbance was monitored 
at 214 nm and the flow rate was 2 ml/min. Fractions were collected 
manually. 
Step 3. One rechromatography of fraction 35 from step 2 on a Vydac 
C 18 RP-HPLC column (4.6 x 250 mm, 5 pm, 300/k; MZ-Analysentech- 
nik, Mainz, Germany) yielded highly purified hBD-1. The same sol- 
vents as in step 2 were used with a gradient from 25% to 50% solvent 
B in 25 rain. Absorbance was monitored at 214 nm and the flow rate 
was 0.75 ml/min. 
2.3. Capillary zone electrophoresis 
Purity of fractions was controlled by capillary zone electrophoresis 
(CZE) with a P/ACE 2000 system and System Gold software (Beckman, 
Mfinchen, Germany). Samples were injected by pressurization for 1 10 
s. The diameter of the uncoated capillary was 75 ~tm and the effective 
and total length were 50 cm and 57 cm, respectively. Peptides were 
separated at a constant current of 120 pA and detected at 200 nm. The 
buffer consisted of 0.1 M sodium phosphate, pH 2.5, containing 0.2 g/1 
hydroxypropylmethylcellulose. 
2.4. Reduction and S-alkylation 
100 pg of purified hBD-1 were dissolved in 95 pl alkylating buffer 
(250 mM Tris-acetate, 6 M guanidinium-HC1, 2 mM EDTA, pH 8.0). 
After addition of 5 pl reducing solution (400 mM DTT in alkylating 
buffer) and incubation for 30 min at 40°C, 20/A of 500 mM iodoacet- 
amide in alkylating buffer were added. Incubation was continued at 
room temperature for 30 min in the dark. The reaction was stopped 
with 0.1% TFA and the carboxamidomethylated p ptide (CAM-pep- 
tide) was immediately purified by RP-HPLC. 
2.5. Peptide sequence analysis 
The amino acid sequence of the native and S-alkylated peptide was 
determined by the edman degradation method on a 473 A sequenator 
(ABI, Weiterstadt, Germany) equipped with MicroCartridge (ABI) 
following the instructions of the manufacturer. Programming, data 
collection and evaluation were perfomed using Model 610A Data Anal- 
ysis software (ABI). 
2.6. Amino acid analysis 
Gas-phase hydrolysis was carried out with a Waters Pico Tag Work- 
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station (Millipore, Eschborn, Germany) with 6 M HC1 for 1 h at 160°C. 
Amino acids were analyzed on a 1090L AminoQuant Analyzer (Hewl- 
ett Packard, Waldbronn, Germany) using precolumn derivatisation 
with OPA and Fmoc [17]. Norvaline and sarcosine were used as internal 
standards at final concentrations of 50 pM. Data were collected and 
evaluated on a HP 300 ChemStation (Hewlett Packard). 
2. 7. Mass determination 
Molecular masses of the native, reduced, and S-alkylated peptide 
were measured on a Sciex API IlI triple-stage quadrupole mass spec- 
trometer with electrospray interface (Perkin-Elmer, Uberlingen, Ger- 
many) in positive-ion mode. Samples were applied with a Harvard 
infusion pump (FMI GmbH, Egelsbach, Germany) at a flow rate of 
5 Hl/min. Data were collected and evaluated with MacSpec Software 
(Perkin-Elmer). 
2.8. Clon&g and characterization of cDNA 
RNA-purification, cDNA first strand synthesis, polymerase chain 
reaction (PCR), and DNA sequencing was performed as described [19]. 
A degenerate PCR sense primer (BDNT; 5'-CCCGGGAATTCTAGA- 
GAYCAYTAYAAYTGYGT-Y) was derived from the N-terminus of 
the peptide sequence. The antisense primer was Unip-2 (5'-CCT- 
GAATTCTAGAGCTCAT]7-3'), the same oligo(dT) primer used for 
cDNA first strand synthesis. Both primers contained an add-on se- 
quence with the recognition sequence for EcoRI. PCR-fragments were 
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cleaved with EcoRI and purified from non-incorporated primers and 
small restriction fragments with Magic-PCR-Preps (Promega, Hei- 
delberg, Germany). Purified PCR-fragments were ligated in the EcoRI 
restriction site of pBluescript II SK+ (Stratagene, Heidelberg, Ger- 
many). Then E. coli XL1-Blue cells were transformed with the products 
and recombinant clones were selected by the blue/white color srceening 
on indicator plates containing IPTG and X-gal. 
3. Results and discussion 
We report the isolation and structural characterization f a 
novel human peptide present in plasma. It shares ome charac- 
teristic properties with bovine neutrophil fl-defensins, TAP 
from bovine trachea, and gallinacins from chicken. Therefore 
this peptide is named human fl-defensin-1 (hBD-1) and repre- 
sents the first human member of the family of fl-defensins. 
The peptide was isolated from 4800 litres of human hemofil- 
trate by a combination of batch extraction, cation-exchange 
chromatography, and RP-HPLC. Peptides were recovered with 
1 M NaC1 after absorbtion to a cation-exchange column and 
precipitated with ammonium sulfate. Ultrafiltration through a 
membrane with a cut-off of 20 kDa was carried out to separate 
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Fig. 1. Purification of hBD-1. (a) Chromatogram of the preparative cation exchange chromatography ( J  absorbance at280 nm, - -  conductivity). 
The marked fraction 40 is further processed. (b) Preparative RP-C4 chromatography of fraction 40 ( J  absorbance at214 nm, - -  gradient in % 
B). The marked fraction 35 contains hBD-1. (c) Analytical RP-C18 chromatography of fraction 35 (~ absorbance at 214 nm, - -  gradient in % 
B) and (d) electropherogram of hBD-1. 
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\ BDNT-> 
1DHYNCVSSGGQCLYS 15 
1 GAY CAY TAY AAY TGY GTC AGC AGT GGA GGG CAA TGT CTC TAT TCT 45 
16 A C P I F T K I Q G T C Y R G 30 
46 GCC TGC CCG ATC TTT ACC AAA ATT CAA GGC ACC TGT TAC AGA GGG 90 
31 K A K C C K * 36 
91 AAG GCC AAG TGC TGC AAG TGA GCTGGGAGTGACCAGAAGAAATGACGCAGAA 142 
143 GTGAAATGAACTTTTTATAAGCATTCTTTTWGGAAAATTGCTTTTGAAGTATAA 201 
d-“nip-Z--/ 
202 AAAAAAAAAAAAAAAAA 218 
Fig. 2. Amino acid sequence and partial cDNA of hBD-1. The upper line represents the amino acid sequence in single letter code. The primers BDNT 
and Unip-2 used for cloning are shown as arrows. The add-on sequences are indicated as small flags. The stop codon is marked with an asterisk 
and the mutative nolvadenvlation signal is underlined. The first 17 nucleotides origin from the degenerate primer BDNT so all possible nucleotides 
for the third cod& position are listed in the sequence (Y = C or T). 
remaining plasma proteins from peptides. In two runs the ul- 
trafiltrate containing the peptides was chromatographed on a 
preparative cation-exchange column and eluted in a linear gra- 
dient (Fig. la). hBD-1 elutes in fraction 40 at 90 min at high 
salt concentration. Further purification by semi-preparative 
RP-HPLC of fraction 40 on a C4 column resolved hBD-1 in 
a peak at 38.8 min in fraction 35 in the complex chromatogram 
(Fig. lb). Rechromatography on an analytical RP-Cl8 column 
resulted in a pure and homogenous peptide (Fig. lc) as judged 
by capillary zone electrophoresis (Fig. Id). 
Sequence analysis of native hBD-1 resulted in a peptide se- 
quence of 36 amino acids. Positions 5, 12, 17, 21, 34 and 35 
showed no PTH-amino acid and were proposed to contain 
cysteines, which are not detected by standard edman degrada- 
tion. Positive identification of cysteines was performed se- 
quencing reduced and S-alkylated hBD-1. All amino acids in- 
cluding the six CAM-cysteines at the supposed positions 5, 12, 
17, 27, 34 and 3.5 were readily detected (Fig. 2). 
hBD-1 was subjected to amino acid analysis to establish the 
amino acid composition. Table 1 is a comparison of the values 
obtained by amino acid analysis and sequence analysis. The 
results of both experiments are consistent. Slightly lower values 
for serine, histidine, threonine and tyrosine in amino acid anal- 
ysis are due to partial destruction during acid hydrolysis. 
Molecular masses of 3928.0 + 0.5 Da for the native peptide 
and 4276.5 t 0.6 Da for the reduced and alkylated peptide were 
measured by electrospray mass spectrometry (Fig. 3). The mass 
difference of 348 Da results from addition of six car- 
boxamidomethylene groups (-CH,CONH,, 58 Da) to the six 
cysteines in hBD-1. Alkylation without prior reduction was not 
successful and the same mass as for the native peptide was 
determined. Reduction without alkylation resulted in a molecu- 
lar mass of 3934.2 + 0.8 Da, a difference of 6 Da relative to 
native hBD-1 (data not shown). The calculated average masses 
of hBD-I with and without three disulfide bridges are 3928.6 
Da and 3934.6 Da, respectively. This is in good agreement with 
the measured masses of the native and reduced peptide. These 
data support the presence of six cysteines as demonstrated by 
amino acid sequence analysis. All cysteines are involved in three 
intramolecular disulfide bonds. 
Based on the peptide sequence a degenerate sense primer 
BDNT was designed with an additional 5’ add-on sequence 
used for subcloning. BDNT covers the first six N-terminal 
Fig. 3. Mass spectra of the (a) native and (b) reduced and alkylated 
peptide. The molecular masses were calculated from multiple charged 
ions as 3928.0 f 0.5 Da from 786.5 Da, 983.5 Da, and 1310.5 Da (a) 
and as 4276.5 ? 0.6 Da from 856.5 Da, 1070.7 Da, and 1426.5 Da(b). 
respectively. 
334 K. I,E Bensch et aL /FEBS Letters 368 (1995) 331-335 
hBD-1 
TAP 
Gal 10t 
Gal 1 
Gal 2 
BNBD-1 
BNBD-2 
BNBD-3 
BNBD-4 
BNBD-5 
BNBD-6 
BNBD-7 
BNBD-8 
BNBD-9 
BNBD-10 
BNBD-11 
BNBD-12 
BNBD-13 
I 
DHYNC 
NPVSC 
GRKSDC 
GRKSDC 
LFC 
10 20 
v S s G~ Q C L Y S AIC----~I F T K I Q G T C 
VRN KI( I C V P I RIC PIG S MK Q I GTC 
FRKN 
FRKS 
- -KN 
DFASCHTNG 
VRNHVTC R I  NR 
pEGVRNHVTC R INR 
pERVRNPQSC RWNM 
pEVVRNPQSC RWNM 
pEGVRNHVTC R I  YG 
pEGVRNFVTC R INR 
VRNFVTC R I  NR 
pEGVRNFVTC R I  NR 
pEGVRS Y L S C WGNR 
G P L SIC R RNG 
GPLSCGRNG 
S G I S G P L SiC G RNG 
C FIC A F L KIC PIY L T L I S 
C ~ C A F L KIC PIS L T L I S 
G C H F G GIC PIS H L I KV  
G IiS L P NR IC  PIG H M I Q I GWC 
G FI~ V P I RIC PIG RTRQ I STC 
G F Z V P I RJC PIG RTRQ I STC 
G VZ I PFLC~VGMRQI  
GV : I P I SC~GNMRQI  
G~=vPIRC~G~r~QI 
G~=VPIRJC~G~QI 
G~ =VPIRC~GHRRQI 
GiZ~LNalC~GRMRQI  I P I R [C~G P M R Q I 
G I P I R IC~V P M R Q I 
I P I RIC PfV P M R Q I ~ T C 
G C 
G C 
30 36 
Y RG KA I .  . K 
IVG RA V RKK 
i 
G]K]C]S R F H L - K R I W 
CIF RP RV ~ R S W 
G  FGPRI  RSW 
Q  FGPRI  RSW 
~ T ClF G P RV P R R 
~ T CIF G P RV P R I- ~ T C[F G R P V K R R W 
~T ClL G P R I E R 
3T  CIL G P Q I'K R 
~TCILGPQI  I R 
~ T CIL A P RV K R 
~TCIF  G R P V K R S W 
$ T CIF G R P V R S W 
JF G R P VIK R S W 
Fig. 4. Sequence comparison of hBD-1 with tracheal antimicrobial peptide (TAP), gallinacins (G al 
fl-defensins 1 13 (BNBD-1 to BNBD-13). Bold type letters represent identical amino acids compared 
boxed. Spacers are inserted for optimal alignment. 
hz, Gal 1 and Gal 2) and bovine neutrophil 
to hBD-1. Highly conserved amino acids are 
amino acids of hBD-1. The antisense primer Unip-2 was also 
used for cDNA first strand synthesis. It is complementary to 
the poly(A) tail of eukaryotic messenger RNA. Specific DNA 
fragments for hBD-1 including the primer sequences with 218 
bp length were amplified from mRNA pools from human kid- 
ney and vagina and subsequently sequenced (Fig. 2). 
The DNA sequences contained an open reading frame with 
a 100% match for the translated amino acid sequence of hBD-1. 
The codon for the last amino acid Lys 36 is followed by a stop 
codon (TGA). The untranslated 3'terminal region is 107 bp in 
length and contains a potential polyadenylation signal (AAT- 
AAA) in the expected istance from the Unip-2 hybridization 
site (poly(A) tail). 
A database search revealed that this novel human peptide has 
a high homology to bovine neutrophil f -defensins (BNBD 1- 
13), tracheal antimicrobial peptide (TAP) from bovine trachea 
and gallinacins (Gal l  a, 1 and 2) from chicken leukocytes (Fig. 
Table 1 
Amino acid composition of hBD-I 
Amino acid F/AAA a //SA b Amino acid ?IAAA a //SA b 
Ala 2.03 2 Leu 1.06 1 
Arg 1,06 1 Lys 4.26 4 
Asp(x) ¢ 2.38 2 Phe 1.00 1 
Cys ND e 6 Pro 0.97 1 
Glu(x) d 2.06 2 Ser 2.38 3 
Gly 4.12 4 Thr 1.71 2 
His 0.88 1 Tyr 2.53 3 
Ile 2.00 2 Val 1.03 1 
aBAAA, number of amino acids determined by amino acid analysis. All 
values relative to phenylalanine. 
%SA, number of amino acids determined by sequence analysis. 
~Asp(x), aspartic acid and asparagine. 
JGlu(x), glutamic acid and glutamate. 
"ND, not determined. 
4). Conserved amino acids are the six cysteines and the residues 
Gly j°, Pro is, Gly 25, Thr 26, and Lys 33. They include a highly 
conserved motif of nine amino acid residues denoted as core- 
motif for fl-defensins [8]. The homology of identical amino 
acids ranges from 25% to 39% for the 13 bovine neutrophil 
fl-defensins, 36% for TAP and 28% to 36% for gallinacins. 
Including chemical similar amino acids the overall homology 
is up to 58%. The cDNA of hBD-I has no homology to the 
cDNA of TAP [t4], the only cDNA published for fl-defensins. 
fl-Defensins belong to the family of cationic and cysteine-rich 
antimicrobial peptides. They are present in leukocytes and ep- 
ithelial cells from the respiratory tract and act in host defense. 
The novel peptide hBD-1 was isolated from blood ultrafiltrate. 
About 3 mg of hBD-1 were isolated from 4800 litres of HF, so 
hBD-1 is present in nanomolar concentration i HF. Concen- 
trations of small peptides in HF with molecular masses below 
10 kDa are the same as in plasma, since they are readily filtered 
during hemofiltration [17]. Therefore it is likely that plasma 
concentrations of hBD-1 in patients with renal failure, from 
whom HF is obtained, are in nanomolar range. Plasma concen- 
trations in normal persons remain to be determined. The source 
which releases hBD-1 into the blood is not known. Since the 
message for hBD-1 is expressed inkidney and vagina as demon- 
strated by the cloning from these tissues, it implies that the 
urogenital tract belongs to those tissues synthesizing en- 
dogenous antibiotic peptides to establish an antimicrobial bar- 
rier. Further investigations will reveal the pattern of expression 
and the biological effect of hBD-1 and its relation to chronic 
renal failure. 
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